HRP20210613T1 - Inhibiranje ionskog kanala prolaznog receptorskog potencijala a1 - Google Patents
Inhibiranje ionskog kanala prolaznog receptorskog potencijala a1 Download PDFInfo
- Publication number
- HRP20210613T1 HRP20210613T1 HRP20210613TT HRP20210613T HRP20210613T1 HR P20210613 T1 HRP20210613 T1 HR P20210613T1 HR P20210613T T HRP20210613T T HR P20210613TT HR P20210613 T HRP20210613 T HR P20210613T HR P20210613 T1 HRP20210613 T1 HR P20210613T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- compound
- pain
- alkyl
- formula
- Prior art date
Links
- 102000004310 Ion Channels Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000001052 transient effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 27
- 208000002193 Pain Diseases 0.000 claims 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical group 0.000 claims 6
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 4
- 206010011224 Cough Diseases 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- 150000001299 aldehydes Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- CYSQMMRFNKGTIL-UHFFFAOYSA-N amino-(hydroxyamino)phosphinic acid Chemical compound NP(=O)(NO)O CYSQMMRFNKGTIL-UHFFFAOYSA-N 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- BSCOYGIDBGKPIX-UHFFFAOYSA-N diazenylphosphonic acid Chemical group OP(O)(=O)N=N BSCOYGIDBGKPIX-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- -1 hydroxy, amino, nitro, sulfhydryl Chemical group 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 150000002576 ketones Chemical group 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical group [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical group [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 150000003573 thiols Chemical group 0.000 claims 2
- 206010006002 Bone pain Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000018380 Chemical injury Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012444 Dermatitis diaper Diseases 0.000 claims 1
- 208000003105 Diaper Rash Diseases 0.000 claims 1
- 208000005373 Dyshidrotic Eczema Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 206010031009 Oral pain Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Discharging, Photosensitive Material Shape In Electrophotography (AREA)
- Electrotherapy Devices (AREA)
- Oscillators With Electromechanical Resonators (AREA)
Claims (16)
1. Spoj Formule (I), ili njegova farmaceutski prihvatljiva sol:
[image]
,
naznačen time što:
R1 je H, C1-C6 alkil, C1-C6 alkenil ili C1-C6 alkinil;
R2 je H, C1-C6 alkil, C1-C6 alkenil ili C1-C6 alkinil, koji može biti supstituiran s jednom ili više skupina R5;
R3 je H, C1-C6 alkil, C1-C6 alkenil ili C1-C6 alkinil;
R4 je halogen, hidroksi, alkoksi, tiol, alkiltio, amino, alkilamino, dialkilamino, cijano, nitro, amido, alkilamido, dialkilamido, tioil, sulfonil, ciklil, heterociklil, aril ili heteroaril, koji može biti supstituiran na jednom ili više položaja s 1-4 skupine R6;
R5 je neovisno H, halogen, alkil, aralkil, alkenil, alkinil, hidroksi, amino, amido, fosfonat, karboksil, eter, alkiltio, halogenalkil, te cijano; i
R6 je neovisno H, halogen, alkil, aralkil, alkenil, alkinil, cikloalkil, hidroksi, amino, nitro, sulfhidril, imino, amido, fosfat, fosfonat, fosfinat, karbonil, karboksil, silil, eter, alkiltio, sulfonil, keton, aldehid, ester, heterocikl, aromatski ili heteroaromatski prsten, halogenalkil, te cijano.
2. Spoj u skladu s prethodnim patentnim zahtjevom, naznačen time što je R1 C1-C6 alkil, izborno -CH3; ili gdje je R1 H; i/ili gdje je R2 C1-C6 alkil; izborno
gdje je R2 -CH3, -CD3 ili -CHF2, ili gdje je R2 H;
i/ili gdje je svaki od R1 i R2 neovisno C1-C6 alkil; gdje svaki od R1 i R2 može biti neovisno -CH3;
i/ili gdje je svaki od R1 i R2 neovisno -CH3, a R3 je H;
i/ili gdje je R3 H; ili
gdje je R3 C1-C6 alkil; ili
gdje je R3 -CH3;
i/ili; gdje je svaki od R1, R2, te R3 neovisno C1-C6 alkil; gdje svaki od R1, R2 i R3 može biti neovisno -CH3.
3. Spoj Formule (I) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je spoj Formule (Ia):
[image]
;
ili gdje je spoj Formule (I) spoj Formule (Ib):
[image]
.
4. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je R4 heterociklil;
i/ili gdje je heterociklil 4- do 8-ročlani prsten;
i/ili gdje je heterociklil spojen preko atoma dušika;
i/ili gdje R4 je supstituiran heterociklil;
i/ili gdje se R4 bira iz skupine koju čine:
[image]
,
[image]
, te
[image]
;
i/ili gdje se R4 bira iz skupine koju čine:
[image]
,
[image]
, te
[image]
;
i m je 1; i/ili gdje se R4 bira iz skupine koju čine:
[image]
,
[image]
, te
[image]
;
i/ili gdje se R4 bira iz skupine koju čine:
[image]
,
[image]
, te
[image]
;
i m je 1; i/ili gdje se R4 bira iz skupine koju čine:
[image]
,
[image]
, te
[image]
;
gdje može biti m je 1, ili 0;
i/ili gdje je R6 alkil, halogenalkil, ili cijano;
i/ili gdje je R6 alkil ili halogenalkil; gdje R6 može biti -CF3; i/ili gdje se R4 bira iz skupine koju čine:
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
, te
[image]
.
5. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je spoj Formule (I) spoj Formule (II):
[image]
,
gdje:
n je cijeli broj od 0 do 4; i
m se bira između cijelih brojeva od 0 do 4;
gdje spoj Formule (I) može biti spoj Formule (IIa):
[image]
,
gdje:
n je cijeli broj od 0 do 4; i
m se bira između cijelih brojeva od 0 do 4;
ili gdje je spoj Formule (I) spoj Formule (IIb):
[image]
,
gdje:
n je cijeli broj od 0 do 4; i
m se bira između cijelih brojeva od 0 do 4.
6. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se spoj bira iz sljedeće skupine:
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
, te
[image]
,
ili njihovih farmaceutski prihvatljivih soli.
7. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je spoj:
[image]
,
ili njegova farmaceutski prihvatljiva sol.
8. Farmaceutski pripravak, naznačen time što sadrži spoj Formule (I), ili njegovu farmaceutski prihvatljivu sol:
[image]
,
gdje:
R2 je H, C1-C6 alkil, C1-C6 alkenil ili C1-C6 alkinil, koji može biti supstituiran s jednom ili više skupina R5;
R3 je H, C1-C6 alkil, C1-C6 alkenil ili C1-C6 alkinil;
R4 je halogen, hidroksi, alkoksi, tiol, alkiltio, amino, alkilamino, dialkilamino, cijano, nitro, amido, alkilamido, dialkilamido, tioil, sulfonil, ciklil, heterociklil, aril ili heteroaril, koji može biti supstituiran na jednom ili više položaja s 1-4 skupine R6;
R5 je neovisno H, halogen, alkil, aralkil, alkenil, alkinil, hidroksi, amino, amido, fosfonat, karboksil, eter, alkiltio, halogenalkil, te cijano; i
R6 je neovisno H, halogen, alkil, aralkil, alkenil, alkinil, cikloalkil, hidroksi, amino, nitro, sulfhidril, imino, amido, fosfat, fosfonat, fosfinat, karbonil, karboksil, silil, eter, alkiltio, sulfonil, keton, aldehid, ester, heterocikl, aromatski ili heteroaromatski prsten, halogenalkil, te cijano.
9. Pripravak u skladu s patentnim zahtjevom 8, naznačen time što je spoj:
[image]
,
ili njegova farmaceutski prihvatljiva sol;
i/ili gdje pripravak sadrži dijastereomerni suvišak veći od ili jednak 99;
i/ili gdje pripravak ima sadržaj vlage manji od ili jednak 0,1%.
10. Pripravak namijenjen upotrebi u liječenju poremećaja kod kojeg posreduje TRPA1 kod subjekta, naznačen time što pripravak sadrži djelotvornu količinu spoja u skladu s bilo kojim od prethodnih patentnih zahtjeva.
11. Pripravak namijenjen upotrebi u liječenju boli kod subjekta, naznačen time što pripravak sadrži djelotvornu količinu spoja u skladu s bilo kojim od prethodnih patentnih zahtjeva;
gdje bol može biti neuropatska bol;
ili gdje je bol upalna bol;
ili gdje je bol PDN ili CIPN;
ili gdje je bol visceralna bol;
ili gdje se bol bira iz skupine koju čine: bol uzrokovana rakom, bol uzrokovana opeklinom, oralna bol, crush i bol uzrokovana ozljedom, bol uzrokovana reznom ranom, kostobolja, bol uzrokovana bolešću srpastih stanica, fibromialgija i muskuloskeletalna bol;
ili gdje je bol uzrokovana hiperalgezijom ili alodinijom.
12. Pripravak namijenjen upotrebi u liječenju upalne bolesti kod subjekta, naznačen time što pripravak sadrži djelotvornu količinu spoja u skladu s bilo kojim od prethodnih patentnih zahtjeva.
13. Pripravak namijenjen upotrebi u liječenju neuropatije kod subjekta, naznačen time što pripravak sadrži djelotvornu količinu spoja u skladu s bilo kojim od prethodnih patentnih zahtjeva;
gdje neuropatija može biti uzrokovana dijabetesom, kemijskom ozljedom, kemoterapijom, te ili traumom.
14. Pripravak namijenjen upotrebi u liječenju dermatološkog poremećaja kod subjekta, naznačen time što pripravak sadrži djelotvornu količinu spoja u skladu s bilo kojim od prethodnih patentnih zahtjeva;
gdje može biti dermatološki poremećaj se bira između atopičnog dermatitisa, akutnog svrbeža, psorijaze, koprivnjače, egzema, dishidrotičnog egzema, afti, te pelenskog osipa.
15. Pripravak namijenjen upotrebi u liječenju plućne bolesti kod subjekta, naznačen time što pripravak sadrži djelotvornu količinu spoja u skladu s bilo kojim od prethodnih patentnih zahtjeva;
gdje plućna bolest može biti opstruktivna bolest; ili gdje je plućna bolest kronična opstruktivna plućna bolest ili astma.
16. Pripravak namijenjen upotrebi u liječenju kašlja kod subjekta, naznačen time što pripravak sadrži djelotvornu količinu spoja u skladu s bilo kojim od prethodnih patentnih zahtjeva;
gdje kašalj može biti kašalj uzrokovan alergijom.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983223P | 2014-04-23 | 2014-04-23 | |
| US201461987272P | 2014-05-01 | 2014-05-01 | |
| PCT/US2015/027353 WO2015164643A1 (en) | 2014-04-23 | 2015-04-23 | Inhibiting the transient receptor potential a1 ion channel |
| EP15722319.9A EP3134410B1 (en) | 2014-04-23 | 2015-04-23 | Inhibiting the transient receptor potential a1 ion channel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210613T1 true HRP20210613T1 (hr) | 2021-05-28 |
Family
ID=53175632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210613TT HRP20210613T1 (hr) | 2014-04-23 | 2021-04-16 | Inhibiranje ionskog kanala prolaznog receptorskog potencijala a1 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20170050966A1 (hr) |
| EP (1) | EP3134410B1 (hr) |
| JP (1) | JP6557680B2 (hr) |
| CN (1) | CN106573934B (hr) |
| AU (1) | AU2015252007B2 (hr) |
| CA (1) | CA2945789C (hr) |
| CY (1) | CY1124243T1 (hr) |
| DK (1) | DK3134410T3 (hr) |
| ES (1) | ES2865173T3 (hr) |
| HR (1) | HRP20210613T1 (hr) |
| HU (1) | HUE054066T2 (hr) |
| LT (1) | LT3134410T (hr) |
| PL (1) | PL3134410T3 (hr) |
| PT (1) | PT3134410T (hr) |
| RS (1) | RS61715B1 (hr) |
| SI (1) | SI3134410T1 (hr) |
| TW (1) | TWI676626B (hr) |
| WO (1) | WO2015164643A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3193880T1 (sl) | 2014-09-19 | 2020-06-30 | Eli Lilly And Company | Inhibicija TRPA1 ionskih kanalčkov |
| EP3554500A1 (en) * | 2016-12-16 | 2019-10-23 | Galderma Research & Development | Trpa1 antagonists for use in the treatment of atopic dermatitis |
| BR112019025611A2 (pt) * | 2017-07-11 | 2020-06-16 | Boehringer Ingelheim International Gmbh | Derivados de xantina substituídos |
| CN111655693B (zh) | 2018-01-31 | 2023-03-28 | 伊莱利利公司 | 抑制瞬时型感受器电位a1离子通道 |
| US20220000966A1 (en) * | 2018-10-23 | 2022-01-06 | George Edward Hoag | Composition and method for treating the lungs |
| FR3114235A1 (fr) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer |
| IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
| WO2023133502A1 (en) * | 2022-01-07 | 2023-07-13 | The Johns Hopkins University | Treatment and prevention of trigeminal neuralgia |
| CN114671875A (zh) * | 2022-04-27 | 2022-06-28 | 成都施贝康生物医药科技有限公司 | 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途 |
| CN114671876B (zh) * | 2022-04-27 | 2023-10-03 | 成都施贝康生物医药科技有限公司 | 新型茶碱类化合物、异构体或盐及其制备方法和用途 |
| CN114656473B (zh) * | 2022-04-27 | 2023-09-29 | 成都施贝康生物医药科技有限公司 | 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途 |
| CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
| CN114656472B (zh) * | 2022-04-27 | 2023-07-04 | 成都施贝康生物医药科技有限公司 | 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006327181A1 (en) | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | TRPA1 inhibitors for treating pain |
| JP2010530901A (ja) * | 2007-06-22 | 2010-09-16 | ハイドラ バイオサイエンシズ インコーポレイテッド | 障害を治療するための方法および組成物 |
| WO2009140517A1 (en) * | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
| US20120046305A1 (en) * | 2008-09-24 | 2012-02-23 | Moran Magdalene M | Methods and compositions for treating respiratory disorders |
| MX2014001551A (es) * | 2011-08-09 | 2014-09-15 | Hydra Biosciences Inc | Inhibicion de canal ionico del potencial receptor transitorio a1 (trpa1). |
| EP2945947B1 (en) * | 2013-01-18 | 2019-12-04 | Merck Sharp & Dohme Corp. | Inhibiting the transient receptor potential a1 ion channel |
| GB201309333D0 (en) * | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
| SI3193880T1 (sl) * | 2014-09-19 | 2020-06-30 | Eli Lilly And Company | Inhibicija TRPA1 ionskih kanalčkov |
| PE20180177A1 (es) * | 2015-02-15 | 2018-01-22 | Hoffmann La Roche | Derivados de 1-(het) arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 |
-
2015
- 2015-04-22 TW TW104112831A patent/TWI676626B/zh active
- 2015-04-23 US US15/305,892 patent/US20170050966A1/en not_active Abandoned
- 2015-04-23 WO PCT/US2015/027353 patent/WO2015164643A1/en active Application Filing
- 2015-04-23 JP JP2016562799A patent/JP6557680B2/ja active Active
- 2015-04-23 SI SI201531549T patent/SI3134410T1/sl unknown
- 2015-04-23 CN CN201580022160.9A patent/CN106573934B/zh active Active
- 2015-04-23 PT PT157223199T patent/PT3134410T/pt unknown
- 2015-04-23 AU AU2015252007A patent/AU2015252007B2/en not_active Ceased
- 2015-04-23 HU HUE15722319A patent/HUE054066T2/hu unknown
- 2015-04-23 DK DK15722319.9T patent/DK3134410T3/da active
- 2015-04-23 CA CA2945789A patent/CA2945789C/en active Active
- 2015-04-23 PL PL15722319T patent/PL3134410T3/pl unknown
- 2015-04-23 LT LTEP15722319.9T patent/LT3134410T/lt unknown
- 2015-04-23 RS RS20210455A patent/RS61715B1/sr unknown
- 2015-04-23 EP EP15722319.9A patent/EP3134410B1/en active Active
- 2015-04-23 ES ES15722319T patent/ES2865173T3/es active Active
-
2018
- 2018-03-29 US US15/940,253 patent/US10428072B2/en active Active
-
2021
- 2021-04-16 HR HRP20210613TT patent/HRP20210613T1/hr unknown
- 2021-05-07 CY CY20211100390T patent/CY1124243T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3134410B1 (en) | 2021-03-10 |
| RS61715B1 (sr) | 2021-05-31 |
| US20170050966A1 (en) | 2017-02-23 |
| TWI676626B (zh) | 2019-11-11 |
| EP3134410A1 (en) | 2017-03-01 |
| AU2015252007A1 (en) | 2016-10-13 |
| CY1124243T1 (el) | 2022-07-22 |
| PL3134410T3 (pl) | 2021-07-12 |
| US20180230149A1 (en) | 2018-08-16 |
| AU2015252007B2 (en) | 2019-08-22 |
| CA2945789A1 (en) | 2015-10-29 |
| WO2015164643A1 (en) | 2015-10-29 |
| CN106573934B (zh) | 2019-10-11 |
| DK3134410T3 (da) | 2021-04-26 |
| CA2945789C (en) | 2022-08-30 |
| HUE054066T2 (hu) | 2021-08-30 |
| LT3134410T (lt) | 2021-04-26 |
| ES2865173T3 (es) | 2021-10-15 |
| TW201625618A (zh) | 2016-07-16 |
| SI3134410T1 (sl) | 2021-04-30 |
| PT3134410T (pt) | 2021-04-22 |
| US10428072B2 (en) | 2019-10-01 |
| JP2017516763A (ja) | 2017-06-22 |
| JP6557680B2 (ja) | 2019-08-07 |
| CN106573934A (zh) | 2017-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210613T1 (hr) | Inhibiranje ionskog kanala prolaznog receptorskog potencijala a1 | |
| PH12018500147A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| PH12018500087A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
| HRP20201343T1 (hr) | Kristalni oblici 5-kloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina | |
| PH12015502038A1 (en) | 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | |
| JP2016512520A5 (hr) | ||
| SI2935307T1 (en) | Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures | |
| HRP20210044T1 (hr) | Farmaceutski prihvatljive soli beta-gvanidinopropionske kiseline sa poboljšanim svojstvima i njihova upotreba | |
| IN2014MN01839A (hr) | ||
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| EA201001129A1 (ru) | Пиримидины в качестве ингибиторов киназы | |
| SI2648726T1 (en) | POLYCYCIC LPA1 ANTAGONIST AND ITS USE | |
| WO2012061418A3 (en) | Benzamides and nicotinamides as syk modulators | |
| MY172924A (en) | Neprilysin inhibitors | |
| EA201001772A1 (ru) | Производные 3,5-диамино-6-хлорпиразин-2-карбоновой кислоты и их применение в качестве блокаторов эпителиальных натриевых каналов для лечения заболеваний дыхательных путей | |
| MX2014011946A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
| BR112014002960A2 (pt) | inibição de canal de íons potencial receptor transiente trpa1 | |
| MX2016008665A (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
| MX2019008626A (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl). | |
| WO2008109991A8 (en) | Inhibitors of carnitine palmitoyltransferase and treating cancer | |
| JP2016529319A5 (hr) | ||
| BR112015021443A2 (pt) | novo sal de abexinostato, forma cristalina associada, um processo para preparação dos mesmos e composições farmacêuticas contendo-os | |
| RU2016137668A (ru) | Новые производные каннабидиол-хинона | |
| FI3572405T3 (fi) | Benzoimidatsol-1,2-yyli amidit kv7 kanavan aktivaattoreina |